Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: are milder immunosuppressive regimens advisable?
Pascual
J
J
Department of Nephrology, Hospital Ramŏn y Cajal, Madrid, Spain.
Crespo
M
M
Mateos
M L
ML
Marcén
R
R
Orofino
L
L
Burgos
F J
FJ
Liaño
F
F
Ortuño
J
J
D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D006085:Graft Survival; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011241:Prednisone